Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
Rhythm Pharmaceuticals' shares dropped after its experimental drug for rare genetic obesity failed to meet the primary goal of its late-stage clinical trial. Meanwhile, rival drugs achieved significant weight loss results, leading to major shifts in the obesity and diabetes drug market. Novo Nordisk's Wegovy® HD received FDA approval, showing remarkable weight loss outcomes.